Is EHC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on De novo hospitals and bed additions, with revenue (ttm) at ~$6.21B. The bear case rests on encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Analysts covering it are spread from $140.00 to $155.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $140.00, +12.2% from the $124.83 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

De novo hospitals and bed additions. Growth here is physical, not promotional. The most optimistic analyst target on EHC is $155.00, +24.2% from the $124.83 price. That figure is only reachable if this thesis works close to its best case.

Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026. The most pessimistic published target is $140.00, +12.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

The largest US operator of inpatient rehabilitation hospitals, growing by adding beds and opening new hospitals, paid mostly by Medicare.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (De novo hospitals and bed additions) stalling in the reported numbers rather than in the narrative, the risk above (encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It operates inpatient rehabilitation hospitals, 176 of them across 39 states and Puerto Rico as of mid-2026. Patients arrive after a stroke, hip fracture, brain or spinal cord injury, or major surgery, and receive intensive physician-supervised therapy before returning home. Medicare is the dominant payer, and Encompass is the largest operator in this category in the United States.

An IRF is a hospital-level setting for patients who need intensive rehabilitation, generally around three hours of therapy a day, under daily physician oversight and 24-hour rehabilitation nursing. It sits between an acute-care hospital and home. Medicare pays IRFs under their own prospective payment system, a fixed amount per discharge set by the patient's condition, age and complexity rather than by length of stay.

It requires that at least 60 percent of a rehabilitation hospital's patients have one of 13 qualifying conditions, including stroke, hip fracture, brain injury, spinal cord injury and amputation. A facility that stays above the threshold is paid under the IRF system. One that falls below is paid as a general acute-care hospital instead, which is a materially worse rate, so compliance is managed closely.